Jay T. Evans, GlaxoSmithKline to Speak at Innate Immunity Conference, Jan 29-31, 2014, San Diego, CA
Jay Evans, Senior Scientist and Investigator at GlaxoSmithKline will give a presentation at the Inaugural Innate Immunity Conference to be held in San Diego, CA on January 29-31, 2014 by GTC.
San Diego, CA, October 09, 2013 --(PR.com)-- Jay Evans, Senior Scientist and Investigator at GlaxoSmithKline will give a presentation at the Inaugural Innate Immunity Conference to be held in San Diego, CA on January 29-31, 2014 by GTC.
Jay Evans, currently leads the pre-clinical innovation team at GSK. Dr. Evans joined GSK Vaccines (formerly Corixa Corporation) in 2000 and has served various roles within the adjuvant research and development center in Hamilton, MT. Prior to joining GSK Vaccines, Dr. Evans worked on HIV immunology and lentiviral gene therapy at University of Texas Southwestern Medical Center and St. Jude Children’s Research Hospital. Dr. Evans holds a B.S. in biology from Pacific Lutheran University and a Ph.D. in molecular and cellular biology from Oregon State University.
The Inaugural Innate Immunity Conference brings together a mix of academic and industry authoritative experts from leading affiliations (such as Mt. Sinai School of Medicine, NIAID, 3M Company, Pfizer Vaccine Research, MedImmune, Harvard School of Medicine, NIH, Nomis Foundation Laboratories for Immunobiology and Microbial Pathogenesis, etc.) to cover many current and relevant aspects of basic, translational or full development in innate immunity and its applicability to human health.
This conference is part of the 2014 Novel Immunotherapeutics Summit, which consists of the following co-located conferences:
1) 6th Immunotherapeutics and Immunomonitoring
2) 12th Cytokines & Inflamation
3) 2nd Immunogenicity and Immunotoxicity
For more information, please visit http://www.gtcbio.com/conference/innate-immunity-overview
Jay Evans, currently leads the pre-clinical innovation team at GSK. Dr. Evans joined GSK Vaccines (formerly Corixa Corporation) in 2000 and has served various roles within the adjuvant research and development center in Hamilton, MT. Prior to joining GSK Vaccines, Dr. Evans worked on HIV immunology and lentiviral gene therapy at University of Texas Southwestern Medical Center and St. Jude Children’s Research Hospital. Dr. Evans holds a B.S. in biology from Pacific Lutheran University and a Ph.D. in molecular and cellular biology from Oregon State University.
The Inaugural Innate Immunity Conference brings together a mix of academic and industry authoritative experts from leading affiliations (such as Mt. Sinai School of Medicine, NIAID, 3M Company, Pfizer Vaccine Research, MedImmune, Harvard School of Medicine, NIH, Nomis Foundation Laboratories for Immunobiology and Microbial Pathogenesis, etc.) to cover many current and relevant aspects of basic, translational or full development in innate immunity and its applicability to human health.
This conference is part of the 2014 Novel Immunotherapeutics Summit, which consists of the following co-located conferences:
1) 6th Immunotherapeutics and Immunomonitoring
2) 12th Cytokines & Inflamation
3) 2nd Immunogenicity and Immunotoxicity
For more information, please visit http://www.gtcbio.com/conference/innate-immunity-overview
Contact
GTC
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Contact
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Categories